Drug Profile


Alternative Names: 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate; Beloranib hemioxalate; CKD-732; TNP-470 analogue; ZGN-433; ZGN-440

Latest Information Update: 02 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Zafgen
  • Class Antineoplastics; Cyclohexanes; Obesity therapies; Sesquiterpenes; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Neuroectodermal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Obesity; Prader-Willi syndrome; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Jul 2016 Discontinued - Phase-I for Colorectal cancer (Combination therapy) in South Korea (IV)
  • 19 Jul 2016 Discontinued - Phase-I for Solid tumours in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top